Anti-PD-1 antibodies for the treatment of B-cell lymphoma Importance of PD-1+ T-cell subsets

被引：4

作者：

Chu, Fuliang

Neelapu, Sattva S. ^{[1
]}

机构：

[1] Univ Texas MD Anderson Canc Ctr, Dept Lymphoma & Myeloma, Houston, TX 77030 USA

来源：

ONCOIMMUNOLOGY | 2014年 / 3卷 / 02期

关键词：

PD-1; clinical trial; T cell; rituximab; lymphoma; FOLLICULAR LYMPHOMA; SAFETY; RITUXIMAB; CD4(+);

D O I：

10.4161/onci.28101

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 [肿瘤学];

摘要：

Monoclonal antibodies specific for programmed cell death 1 (PDCD1, best known as PD-1) have been shown to mediate antineoplastic effects in follicular lymphoma patients. However, the relative proportion of intratumoral PD-1(+) T-cell subsets, in particular follicular helper T cells (which exert pro-tumor functions) and effector T cells (which have anticancer activity), may impact clinical outcome, and should therefore be carefully considered for patient selection in this setting.

引用

页数：3

共 10 条

[1]

Characterization of intratumoral follicular helper T cells in follicular lymphoma: role in the survival of malignant B cells [J].

Ame-Thomas, P. ;

Le Priol, J. ;

Yssel, H. ;

Caron, G. ;

Pangault, C. ;

Jean, R. ;

Martin, N. ;

Marafioti, T. ;

Gaulard, P. ;

Lamy, T. ;

Fest, T. ;

Semana, G. ;

Tarte, K. .

LEUKEMIA, 2012, 26 (05) :1053-1063

[2]

Follicular regulatory T cells expressing Foxp3 and Bcl-6 suppress germinal center reactions [J].

Chung, Yeonseok ;

Tanaka, Shinya ;

Chu, Fuliang ;

Nurieva, Roza I. ;

Martinez, Gustavo J. ;

Rawal, Seema ;

Wang, Yi-Hong ;

Lim, Hoyong ;

Reynolds, Joseph M. ;

Zhou, Xiao-hui ;

Fan, Hui-min ;

Liu, Zhong-ming ;

Neelapu, Sattva S. ;

Dong, Chen .

NATURE MEDICINE, 2011, 17 (08) :983-U102

[3]

Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma:: Safety and efficacy of re-treatment [J].

Davis, TA ;

Grillo-López, AJ ;

White, CA ;

McLaughlin, P ;

Czuczman, MS ;

Link, BK ;

Maloney, DG ;

Weaver, RL ;

Rosenberg, J ;

Levy, R .

JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (17) :3135-3143

[4]

Safety and Tumor Responses with Lambrolizumab (Anti-PD-1) in Melanoma [J].

Hamid, Omid ;

Robert, Caroline ;

Daud, Adil ;

Hodi, F. Stephen ;

Hwu, Wen-Jen ;

Kefford, Richard ;

Wolchok, Jedd D. ;

Hersey, Peter ;

Joseph, Richard W. ;

Weber, Jeffrey S. ;

Dronca, Roxana ;

Gangadhar, Tara C. ;

Patnaik, Amita ;

Zarour, Hassane ;

Joshua, Anthony M. ;

Gergich, Kevin ;

Elassaiss-Schaap, Jeroen ;

Algazi, Alain ;

Mateus, Christine ;

Boasberg, Peter ;

Tumeh, Paul C. ;

Chmielowski, Bartosz ;

Ebbinghaus, Scot W. ;

Li, Xiaoyun Nicole ;

Kang, S. Peter ;

Ribas, Antoni .

NEW ENGLAND JOURNAL OF MEDICINE, 2013, 369 (02) :134-144

[5]

A novel strategy for rapid and efficient isolation of human tumor-specific CD4+ and CD8+ T-cell clones [J].

Lee, Seung-Tae ;

Liu, Shujuan ;

Radvanyi, Laszlo ;

Sukhumalchandra, Pariya ;

Molldrem, Jeffrey J. ;

Wieder, Eric D. ;

Hwu, Patrick ;

Liu, Yong-Jun ;

Kwak, Larry W. ;

Lizee, Gregory ;

Neelapu, Sattva S. .

JOURNAL OF IMMUNOLOGICAL METHODS, 2008, 331 (1-2) :13-26

[6]

Cross Talk between Follicular Th Cells and Tumor Cells in Human Follicular Lymphoma Promotes Immune Evasion in the Tumor Microenvironment [J].

Rawal, Seema ;

Chu, Fuliang ;

Zhang, Min ;

Park, Hyun Jun ;

Nattamai, Durga ;

Kannan, Shibichakravarthy ;

Sharma, Rakesh ;

Delgado, David ;

Chou, Tina ;

Lin, Heather Y. ;

Baladandayuthapani, Veerabhadran ;

Luong, Amber ;

Vega, Francisco ;

Fowler, Nathan ;

Dong, Chen ;

Davis, R. Eric ;

Neelapu, Sattva S. .

JOURNAL OF IMMUNOLOGY, 2013, 190 (12) :6681-6693

[7]

Colocalization of Inflammatory Response with B7-H1 Expression in Human Melanocytic Lesions Supports an Adaptive Resistance Mechanism of Immune Escape [J].

Taube, Janis M. ;

Anders, Robert A. ;

Young, Geoffrey D. ;

Xu, Haiying ;

Sharma, Rajni ;

McMiller, Tracee L. ;

Chen, Shuming ;

Klein, Alison P. ;

Pardoll, Drew M. ;

Topalian, Suzanne L. ;

Chen, Lieping .

SCIENCE TRANSLATIONAL MEDICINE, 2012, 4 (127)

[8]

Safety, Activity, and Immune Correlates of Anti-PD-1 Antibody in Cancer [J].

Topalian, Suzanne L. ;

Hodi, F. Stephen ;

Brahmer, Julie R. ;

Gettinger, Scott N. ;

Smith, David C. ;

McDermott, David F. ;

Powderly, John D. ;

Carvajal, Richard D. ;

Sosman, Jeffrey A. ;

Atkins, Michael B. ;

Leming, Philip D. ;

Spigel, David R. ;

Antonia, Scott J. ;

Horn, Leora ;

Drake, Charles G. ;

Pardoll, Drew M. ;

Chen, Lieping ;

Sharfman, William H. ;

Anders, Robert A. ;

Taube, Janis M. ;

McMiller, Tracee L. ;

Xu, Haiying ;

Korman, Alan J. ;

Jure-Kunkel, Maria ;

Agrawal, Shruti ;

McDonald, Daniel ;

Kollia, Georgia D. ;

Gupta, Ashok ;

Wigginton, Jon M. ;

Sznol, Mario .

NEW ENGLAND JOURNAL OF MEDICINE, 2012, 366 (26) :2443-2454

[9]

Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial [J].

Westin, Jason R. ;

Chu, Fuliang ;

Zhang, Min ;

Fayad, Luis E. ;

Kwak, Larry W. ;

Fowler, Nathan ;

Romaguera, Jorge ;

Hagemeister, Fredrick ;

Fanale, Michelle ;

Samaniego, Felipe ;

Feng, Lei ;

Baladandayuthapani, Veerabhadran ;

Wang, Zhiqiang ;

Ma, Wencai ;

Gao, Yanli ;

Wallace, Michael ;

Vence, Luis M. ;

Radvanyi, Laszlo ;

Muzzafar, Tariq ;

Rotem-Yehudar, Rinat ;

Davis, R. Eric ;

Neelapu, Sattva S. .

LANCET ONCOLOGY, 2014, 15 (01) :69-77

[10]

Intratumoral CD4+CD25+ regulatory T-cell-mediated suppression of infiltrating CD4+ T cells in B-cell non-Hodgkin lymphoma [J].

Yang, ZZ ;

Novak, AJ ;

Stenson, MJ ;

Witzig, TE ;

Ansell, SM .

BLOOD, 2006, 107 (09) :3639-3646

← 1 →